

Information for Vermont Prescribers of Prescription Drugs (Long Form)

ATTRUBY™ (acoramidis) tablets

- This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product’s FDA-approved label and indication for further information.
- The prices listed below are Wholesale Acquisition Cost (“WAC”) as established and made available to the public by a third-party publisher or as calculated from data made available to the public by a third party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
- The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness of all the products listed. For simplicity, only the smallest package sizes available for each product are included

Product Name	Manufacturer	NDC or UPC	Package Size	WAC per Pack	WAC per Pill
Marketed Product					
ATTRUBY™ (acoramidis) tablets	BridgeBio Inc.	82228-0712-28	112	\$18,759.12	\$167.49
Other Products					
VYNDAMAX® (tafamidis) capsules	Pfizer	00069-1975-40	30	\$22,332.29	\$744.40
VYNDAQEL® (tafamidis meglumine) capsules	Pfizer	00069-8730-30	120	\$22,332.29	\$744.40

Source: FirstDataBank, 11-26-2024

©2024 BridgeBio Pharma, Inc. All rights reserved. MAT-US—443 V1